Centessa Pharmaceuticals plc (CNTA)
NASDAQ: CNTA · Real-Time Price · USD
39.75
-0.06 (-0.15%)
May 29, 2026, 12:16 PM EDT - Market open
Centessa Pharmaceuticals Revenue
In the year 2025, Centessa Pharmaceuticals had annual revenue of $15.00M.
Revenue (ttm)
$15.00M
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
129
Market Cap
6.15B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 15.00M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 6.85M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 827.11M |
| Mirum Pharmaceuticals | 569.61M |
| Rhythm Pharmaceuticals | 217.17M |
| Protagonist Therapeutics | 74.06M |
| Kymera Therapeutics | 51.48M |
CNTA News
- 22 days ago - Centessa Pharmaceuticals Proxy statement: Proxy filing - Filings
- 24 days ago - Centessa Pharmaceuticals Quarterly report: Q1 2026 - Filings
- 4 weeks ago - Centessa Pharmaceuticals Proxy statement: Proxy filing - Filings
- 5 weeks ago - Centessa downgraded to Equal Weight from Overweight at Wells Fargo - TheFly
- 6 weeks ago - Centessa Pharmaceuticals Proxy statement: Proxy filing - Filings
- 6 weeks ago - Centessa Pharmaceuticals Proxy statement: Proxy filing - Filings
- 6 weeks ago - Centessa downgraded to Hold from Buy at Truist - TheFly
- 2 months ago - Centessa downgraded to Neutral from Buy at Guggenheim - TheFly